Over 180 companies from different regions across the globe presently claim to provide services for the development of companion diagnostic.

Health & Fitness / Biotech, Health, market, Pharma, Research / By /

It is estimated that around 80% of innovator companies rely on external companion diagnostic developers, mostly owing to the lack of the required in-house expertise. On the other hand, there are numerous contract service providers, offering vast portfolios of services for diagnostic test / assay development. Such companies are known to possess extensive technical knowledge, and experience in working with cutting-edge analytical tools and technologies, such as in situ hybridization (ISH), immunohistochemistry (IHC), next generation sequencing (NGS), polymerase chain reaction (PCR).

Advertisements
WP Rocket - WordPress Caching Plugin

To  order this 320+ page report, which features 120+ figures and 115+ tables, please visit this link 

The USD 800+ million (by 2030) financial opportunity within the companion diagnostics development services market has been analysed across the following segments:

  • Type of Service Offered
  • Feasibility Studies
  • Assay Development
  • Analytical Validation
  • Clinical Validation
  • Type of Assay Technique Used
  • in situ hybridization / Immunohistochemistry
  • Next Generation Sequencing
  • Polymerase Chain Reaction
  • Others
  • Key geographical regions
  • North America
  • Europe
  • Asia Pacific

The report features inputs from eminent industry stakeholders, according to whom the development of companion diagnostics is largely outsourced, owing to the exorbitant costs associated with the setting-up of in-house expertise / capabilities. The report includes detailed transcripts of discussions held with the following experts:

  • Anton Iliuk (President and Chief Technology Officer, Tymora Analytica)
  • Paul Kortschak (Senior Vice President, Novodiax)
  • Pablo Ortiz (Chief Executive officer, OWL Metabolomics)
  • Lawrence M. Weiss (Chief Scientific Officer, NeoGenomics Laboratories)

Table of Contents

  1. Preface

    2. Executive Summary
    Introduction

  2. Market Landscape
  3. Company Profiles
  4. Partnerships and Collaborations
  5. Likely Partner Analysis
  6. Company Competitiveness Analysis
  7. Stakeholder Needs Analysis
  8. Value Chain Analysis
  9. Clinical Research on Cancer Biomarkers: Big Pharma Perspective
  10. Market Forecast And Opportunity Analysis
  11. Executive Insights
  12. Appendix 1: Tabulated Data
  13. Appendix 2: List of Companies and Organizations

To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/immune-checkpoint-inhibitors/303.html

Contact Details

Gaurav Chaudhary

+1 (415) 800 3415

gaurav.chaudhary@rootsanalysis.com

Related Posts